Arca
Skip to content

Metabolic dysfunction-associated steatohepatitis

Drug research and approvals for metabolic dysfunction-associated steatohepatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 97 studies of metabolic dysfunction-associated steatohepatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, and the EU has 2 authorised medicines for it.

  • Recruiting worldwide: 97
  • Trials authorized in Canada: 9
  • FDA orphan approvals: 0
  • EU medicines: 2

Recruiting Now

Newest start dates first, of 97 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

Newest first; search them all in Canada trials
Jul 22, 2026A phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult…EFIMOSFERMIN ALFA (GSK6519754)GSKPending
Jul 21, 2026A phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety and efficacy of efimosfermin alfa injection in adult…EFIMOSFERMIN ALFA (GSK6519754)GSKOngoing
Jul 14, 2026A phase 2b, randomized, double-blind, placebo-controlled study of aln-cideb in adults with fibrotic metabolic dysfunction associated steatohepatitis (mash)ALN-1699976 (ALN-CIDEB)RegeneronPending
Apr 30, 2026A phase 3, randomized, double-blind, placebo-controlled, 3-arm study to investigate the safety and tolerability of efimosfermin alfa in participants with known…EFIMOSFERMIN ALFA (GSK6519754)GSKOngoing
Apr 29, 2026A phase 3, randomized, double-blind, placebo-controlled, 3-arm study to investigate the safety and efficacy of efimosfermin alfa in participants with…GSK6519754 (EFIMOSFERMIN ALFA)GSKOngoing
Dec 12, 2025A phase IIa double-blind, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of bi 3802876 in participants…BI 3802876Boehringer Ingelheim Pharmaceuticals, Inc.Pending
Jul 23, 2024A phase 3 study to evaluate the efficacy and safety of pegozafermin in subjects with compensated cirrhosis due to metabolic dysfunction-associated…PEGOZAFERMIN (BIO89-100)RocheOngoing
Jun 6, 2024A phase 2a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of efinopegdutide (mk-6024) in adults with compensated…MK-6024Merck & Co. (MSD)Closed
May 3, 2024A phase 3 study to evaluate the efficacy and safety of pegozafermin in subjects with metabolic dysfunction associated steatohepatitis (mash) and fibrosisBIO89-100RocheOngoing

Medicines Authorised in the EU

Newest first
Mar 26, 2026KayshildsemaglutideNovo Nordisk A/SEMA ↗
Aug 18, 2025RezdiffraresmetiromMadrigal Pharmaceuticals EU LimitedEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.